biogen_austria_238

Biogen names haemophilia spin-off Bioverativ

August 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ

Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …

Experimental stem cell treatment shows promise in rheumatoid arthritis

August 10, 2016
Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment

Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …

takeda_tokyo_hq

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016
Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …

imlygic_amgen

NICE recommends Amgen’s Imlygic for advanced skin cancer

August 9, 2016
Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer

NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …

pharma_pill_manufacturing

Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat

August 9, 2016
Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia

Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …

ema_inside

New therapy wins EMA orphan drug designation for ALS

August 9, 2016
Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation

French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …

astrazeneca_building_white

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

August 9, 2016
Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …

joseph_papa

Management shake-up at Valeant as Papa expands senior team

August 9, 2016
Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up

Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …

merckincweb2

FDA approves MSD’s Keytruda for head and neck cancer treatment

August 8, 2016
Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda

The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …

bms

SMC reverses decision on Opdivo in advanced skin cancer

August 8, 2016
Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …

Apellis Pharmaceuticals appoints Dr Robert Kim as CMO

August 8, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment

Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …

humira_abbott_

AbbVie files lawsuit against Amgen over Humira copy

August 8, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …

test_results

The power of PrEP

August 8, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug

Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …

indiaflag

Opdivo and Keytruda set for India launches by end of year

August 8, 2016
Sales and Marketing India, keytruda, launch, opdivo

Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …

4741451457_6344b99835_z_-_copy

‘Game changer’ asthma pill sees significant reduction in severe symptoms

August 8, 2016
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester

A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …

merck_and_co

MSD files Lantus biosimilar with FDA

August 8, 2016
Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …

opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …

4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016
Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report

August 5, 2016
Medical Communications, Research and Development medicare reform, patients' groups, public citizen

An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …

The Gateway to Local Adoption Series

Latest content